Jiansong Wang

Jiansong Wang

Auto-generated profile, based on publicly available information

Jiansong Wang

Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, PR China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
SXShiwei Xiao
Shiwei Xiao
YZYigang Zuo
Yigang Zuo
YLYanan Li
Yanan Li
YHYinglong Huang
Yinglong Huang
SFShi Fu
Shi Fu
JWJiansong Wang
Jiansong Wang
Bladder cancer (BC) is the most common genitourinary malignancy worldwide, and its aetiology and pathogenesis remain unclear. Accumulating evidence has shown that HAGLROS is closely related to the occurrence and progression of various cancers. However, the biological functions and underlying mechanisms of HAGLROS in BC remain unknown. In the present study, the expression of HAGLROS in BC was determined by public dataset analysis, transcriptome sequencing analysis, qRT–PCR and ISH assays. Gain- or loss-of-function assays were performed to study the biological roles of HAGLROS in BC cells and nude mouse xenograft model. Bioinformatic analysis, qRT–PCR, western blot, immunohistochemistry, FISH assays, subcellular fractionation assays and luciferase reporter assays were performed to explore the underlying molecular mechanisms of HAGLROS in BC. Here, we found that HAGLROS expression is significantly upregulated in BC tissues and cells, and elevated HAGLROS expression was related to higher pathologic grade and advanced clinical stage, which is significant for BC diagnosis. HAGLROS can enhance the growth and metastasis of BC in vitro and in vivo. Furthermore, miR-330-5p downregulation reversed the BC cells proliferation, migration and invasion inhibited by silencing HAGLROS. SPRR1B silencing restored the malignant phenotypes of BC cells promoted by miR-330--5p inhibitor. Mechanistically, we found that HAGLROS functions as a microRNA sponge to positively regulate SPRR1B expression by sponging miR-330-5p. Together, these results demonstrate that HAGLROS plays an oncogenic role and may serve as a potential biomarker for the diagnosis and treatment of BC.

1 May 2024
Verified
Journal Article
Closed access
JWJiansong Wang
Jiansong Wang
JLJianjun Luo
Jianjun Luo
XWXuecheng Wu
Xuecheng Wu
ZLZhuo Li
Zhuo Li

1 January 2019 in Clinical Laboratory
Verified
Journal Article
Closed access
YHYinglong Huang
Yinglong Huang
TLTing Luan
Ting Luan
XBXin Bao
Xin Bao
SFShi Fu
Shi Fu
NLNing Li
Ning Li
JWJiansong Wang
Jiansong Wang
Chemotherapy constitutes one of the most important adjuvant treatments for bladder cancer. However, many patients usually develop chemoresistance during chemotherapy. At present, lncRNA has been confirmed not only to be involved in tumorigenesis and progression, but also in tumor chemoresistance. However, the relationship between lncRNAs and chemoresistance of bladder cancer have been rarely reported. The novel lncRNA-KMU15 was screened by lncRNAs microarray and determination of IC50 in bladder cancer. The expression of KMU15 was evaluated by qRT-PCR. The correlation between KMU15 and clinicopathological parameters was analyzed from clinical cases. The effects of KMU15 on the biological behavior and chemoresistance were investigated by [3H]-TdR incorporation assay and other experiments. The effects of KMU15 on the growth of xenograft tumors and the survival of nude mice under cisplatin were examined in a xenograft mouse model. We confirmed that KMU15 was expressed higher in bladder cancer tissues than paired control tissues. Moreover, the expression of KMU15 was significantly positively correlated with the grade, stage, metastasis, and recurrence of bladder cancer and was significantly negatively correlated with the prognosis. In addition, KMU15 knockdown could significantly inhibit bladder cell proliferation, adhesion, migration, and chemoresistance and promoted apoptosis. Knockdown of KMU15 inhibited the growth of xenografts in nude mice and significantly prolonged the survival of tumor-bearing mice under cisplatin. The novel lncRNA KMU15, which is highly expressed in bladder cancer tissues, could promote the proliferation and progression and was closely related to the malignant degree of bladder cancer. It could also significantly enhance the chemoresistance of bladder cancer cells. Therefore, it was expected to be a new therapy target for bladder cancer and a potential prognosis biomarker for chemotherapy.

7 July 2021 in Research Square
Verified
Preprint
Open access
PDF file
SXShiwei Xiao
Shiwei Xiao
YZYigang Zuo
Yigang Zuo
YHYinglong Huang
Yinglong Huang
YLYanan Li
Yanan Li
DYDongbo Yuan
Dongbo Yuan
JWJiansong Wang
Jiansong Wang
BackgroundBladder cancer (BC) is a serious urinary tract malignancy with high incidences and deaths. Here, we aim to explore the OS-related lncRNAs and mRNAs, and constructed a reliable predicting model for accurately predict BC prognosis. Methods3 matched BC tumor samples and adjacent normal samples were processed by whole transcriptome sequencing. Differentially expressed lncRNAs and mRNAs (DE-lncRNAs and DE-mRNAs) were identified with the thresholds |log2 (FC) |>2 and p value 0.5 and p value0.5 and p value<0.05. And the biofunction was determined by Gene Set Enrichment Analysis (GSEA). ResultsA total 2210 DE-lncTNAs and 2334 DE-mRNAs were identified based on whole transcriptome sequencing. And a total 3724 DE-lncRNAs and 2689 DE-mRNAs were identified based on TCGA database. Then, 137 DE-lncRNAs and 278 DE-mRNAs were screened by overlapping RNA sequencing data and TCGA data. A total 13 gene signature were identified to be closely related with OS in BC. Moreover, these 13-OS-related gene signature were identified as independent risk factors with clinical risk factors. Then, a nomogram was constructed and confirmed as the calibration and accuracy predicating model for OS in BC. Finally, a total 739 DEGs were identified between high-risk and low-risk groups, most of DEGs enriched in immune-related pathways. And an OS-related ceRNA network was selected based on 13-OS-related signature. ConclusionOur finding provided novel OS-related prognostic signature and reliable predicting model for BC patients, which might facilitate individualized treatment and prognostic evaluation.